Actual issues of interferonotherapy


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

One of the main links in immunoregulation is the interferon system (IFN). It includes the mechanisms of innate and adaptive immune response, is the first line of defense against viral and other intracellular infections, and it's involved in maintaining the homeostasis of the body. The therapeutic potential of interferon preparations is currently under special attention. The data of various studies cited in this article confirm the need to form clear indications for prescribing this group of drugs. It is important for clinicians to evaluate the clinical risks and benefits of administering interferon therapy.

Full Text

Restricted Access

About the authors

Boris M. Blokhin

«N.I. Pirogov Russian national research medical university» FSBEI of HE of the Ministry of Healthcare of Russia

Email: blokhinb@gmail.com
MD, professor, head of the Department of polyclinic and emergency pediatrics of pediatric faculty

Anastasia D. Prokhorova

«N.I. Pirogov Russian national research medical university» FSBEI of HE of the Ministry of Healthcare of Russia

Email: prohorovaa525@gmail.com
assistant of the Department of polyclinic and emergency pediatrics of pediatric faculty

Aliya S. Suyundukova

«N.I. Pirogov Russian national research medical university» FSBEI of HE of the Ministry of Healthcare of Russia

Email: a.s.suyundukova@hotmail.com
PhD, associate professor of the Department of outpatient and emergency pediatrics of the pediatric faculty

References

  1. Samuel C.E. Antiviral actions of interferons. Clin Microbiol Rev. 2001 Oct; 14(4): 778-809, table of contents.
  2. Bandurska K., Krol I., Myga-Nowak M. Interferons: between structure and function. Postepy Hig Med Dosw (Online). 2014 May 6; 68: 428-40.
  3. Ершов Ф.И., Наровлянский А.Н. Основные итоги изучения системы интерферона к 2011 году. В сборнике Интерферон-2011. Под ред. акад. РАМН, проф. Ф.И. Ершова и проф. А.Н. Наровлянского. Москва, 2012. С. 14-34.
  4. Park S.H., Kang K., Giannopoulou E. et al. Type I interferons and the cytokine TNF cooperatively reprogram the macrophage epigenome to promote inflammatory activation. Nat Immunol. 2017 Oct; 18(10): 1104-16.
  5. Lachova V., Skorvanova L., Svetlikova D. et al. Comparison of transcriptional profiles of interferons, CXCL10 and RIG-1 in influenza infected A549 cells stimulated with exogenous interferons. Acta Virol. 2017; 61(2): 183-90.
  6. Малиновская В.В. Онтогенез системы интерферона и проблемы терапии в неонатальном периоде. В сборнике Интерферон-2011. Под ред. акад. РАМН, проф. Ф.И. Ершова и проф. А.Н. Наровлянского. Москва, 2012. С. 35-51.
  7. Sheng Y.J., Xu S.S., Li X.J. et al. Low birth weight contributed to increased serum IL-6 levels in infantile respiratory syncytial virus infection. BMC Pediatr. 2017 Dec 16; 17(1): 205.
  8. Frémond M.L., Uggenti C., Van Eyck L. et al. Brief Report: Blockade of TANK-Binding Kinase 1/IKK Inhibits Mutant Stimulator of Interferon Genes (STING)-Mediated Inflammatory Responses in Human Peripheral Blood Mononuclear Cells. Arthritis Rheumatol. 2017 Jul; 69(7): 1495-501.
  9. Maughan A. Ogbuagu. Pegylated interferon alpha 2a for the treatment of hepatitis C virus infection. O.Expert Opin Drug Metab Toxicol. 2018 Feb; 14(2): 219-27.
  10. Herrington-Symes A., Choi J.W., Brocchini S. Interferon dimers: IFN-PEG-IFN. J Drug Target. 2017 Nov - Dec; 25(9-10): 881-90.
  11. Ершов Ф.И., Шульдяков А.А., Романцов М.Г., Ляпина Е.П., Соболева Л.А. Результаты и перспективы использования индукторов интерферона в лечении инфекционных болезней. Вестник Российской академии медицинских наук. 2013; 10: 46-52.
  12. Zhang K.J., Yin X.F., Yang Y.Q. et al. A Potent In Vivo Antitumor Efficacy of Novel Recombinant Type I Interferon. Clin Cancer Res. 2017 Apr 15; 23(8): 2038-49
  13. Rizza P., Moretti F., Capone I., Belardelli F. Role of type I interferon in inducing a protective immune response: perspectives for clinical applications. Cytokine Growth Factor Rev. 2015 Apr; 26(2): 195-201.
  14. Мухачева М.В., Бейн Б.Н. Роль интерферонов в иммунитете у больных с церебральными опухолями. Фундаментальные исследования. 2015; 1-7: 1486-1490.
  15. Симоненко В.Б., Дулин П.А., Маканин М.А. Возможности таргетной терапии нейроэндокринных опухолей. Клиническая медицина. 2014; 92(8): 5-14.
  16. Глазкова Н.Н. Иммуномодуляторы в лечении рака. Вестник Калужского университета. 2016; 2: 18-28.
  17. Tong R., Feng L, Zhang L. et al. Decreased Interferon Alpha/Beta Signature Associated with Human Lung Tumorigenesis. J Interferon Cytokine Res. 2015 Dec; 35(12): 963-68.
  18. Buoncervello M., Romagnoli G., Buccarelli M. et al. IFN-a potentiates the direct and immune-mediated antitumor effects of epigenetic drugs on both metastatic and stem cells of colorectal cancer. Oncotarget. 2016 May 3; 7(18): 26361-73. doi: 10.18632/oncotarget.8379.
  19. Liu X., Lu J., He M.L. et al. Antitumor effects of interferon-alpha on cell growth and metastasis in human nasopharyngeal carcinoma. Curr Cancer Drug Targets. 2012 Jun; 12(5): 561-70.
  20. Yin H., Chen N., Guo R. et al. Antitumor potential of a synthetic interferon-alpha/PLGF-2 positive charge peptide hybrid molecule in pancreatic cancer cells. Sci Rep. 2015 Nov 20; 5: 16975.
  21. Skov V., Riley C.H., Thomassen et al. The impact of interferon-alpha2 on HLA genes in patients with polycythemia vera and related neoplasms./ M,Leuk Lymphoma. 2017 Aug; 58(8): 1914-21.
  22. Santak G., Santak M., Forcic D. Comparison of antitumor effects of native and recombinant human interferon-a on non-small cell lung cancer cells. Anticancer Res. 2013 May; 33(5): 2043-46.
  23. Абатуров А.Е., Юлиш Е.И. Роль интерферонов в защите респираторного тракта. Часть 2. Механизмы действия интерферонов. Здоровье ребенка. 2007; 6: 136-144.
  24. Ghodke-Puranik Y., Dorschner J.M., Vsetecka D.M. et al. Lupus-Associated Functional Polymorphism in PNP Causes Cell Cycle Abnormalities and Interferon Pathway Activation in Human Immune Cells. Arthritis Rheumatol. 2017 Dec; 69(12): 2328-37.
  25. Imran M., Waheed Y., Manzoor S. et al. Interaction of Hepatitis C virus proteins with pattern recognition receptors. Virol J. 2012 Jun 22; 9: 126.
  26. Rönnblom L. The importance of the type I interferon system in autoimmunity. Clin Exp Rheumatol. 2016 Jul-Aug; 34(4 Suppl 98): 21-4.
  27. Torigoe M., Iwata S., Nakayamada S. et al. Metabolic Reprogramming Commits Differentiation of Human CD27+IgD+ B Cells to Plasmablasts or CD27-IgD- Cells. J Immunol. 2017 Jul 15; 199(2): 425-34.
  28. Jin Z., Fan J, Zhang Y. et al. Comparison of morphology, phenotypes and function between cultured human IL-4-DC and IFN-DC. Mol Med Rep. 2017 Nov; 16(5): 7345-54.
  29. Murayama G., Furusawa N., Chiba A. et al. Enhanced IFN-a production is associated with increased TLR7 retention in the lysosomes of palasmacytoid dendritic cells in systemic lupus erythematosus. Arthritis Res Ther. 2017 Oct 19; 19(1): 234.
  30. Imgenberg-Kreuz J., Sandling J.K., Björk A. et al. Transcription profiling of peripheral B cells in antibody-positive primary Sjögren's syndrome reveals upregulated expression of CX3CR1 and a type I and type II interferon signature. Scand J Immunol. 2018 May; 87(5): e12662.
  31. Ghodke-Puranik Y., Dorschner J.M., Vsetecka D.M. et al. Lupus-Associated Functional Polymorphism in PNP Causes Cell Cycle Abnormalities and Interferon Pathway Activation in Human Immune Cells. Arthritis Rheumatol. 2017 Dec; 69(12): 2328-37.
  32. Sossau D., Kofler L., Eigentler T. Type 1 diabetes mellitus caused by treatment with low-dose interferon-a in a melanoma patient. Melanoma Res. 2017 Oct; 27(5): 516-18.
  33. Lombardi A., Tsomos E., Hammerstad S.S., Tomer Y. Interferon alpha: The key trigger of type 1 diabetes. J Autoimmun. 2018 Aug 14. pii: S0896-8411(18)30323-8.
  34. Khan W.A., Qureshi J.A. Increased binding of circulating systemic lupus erythematosus autoantibodies to recombinant interferon alpha 2b. APMIS. 2015 Dec; 123(12): 1016-24.
  35. Heim M.H. Innate immunity and HCV. J Hepatol. 2013 Mar; 58(3): 564-74.
  36. Haldipur B., Bhukya P.L., Arankalle V., Lole K. Positive Regulation of Hepatitis E Virus Replication by MicroRNA-122. J Virol. 2018 May 14; 92(11). pii: e01999-17.
  37. Davidson S., McCabe T.M., Crotta S. et al. IFNÀ is a potent anti-influenza therapeutic without the inflammatory side effects of IFNa treatment. EMBO Mol Med. 2016 Sep 1; 8(9): 1099-112.
  38. Como C.N., Pearce C.M., Cohrs R.J., Baird N.L. Interleukin-6 and type 1 interferons inhibit varicella zoster virus replication in human neurons. Virology. 2018 Sep; 522: 13-8.
  39. Tang L.S.Y., Covert E., Wilson E., Kottilil S. Chronic Hepatitis B Infection: A Review. JAMA. 2018 May 1; 319(17): 1802-13.
  40. Friedman A., Siewe N. Chronic hepatitis B virus and liver fibrosis: A mathematical model. PLoS One. 2018 Apr 10; 13(4): e0195037.
  41. Maughan A., Ogbuagu O. Pegylated interferon alpha 2a for the treatment of hepatitis C virus infection. Expert Opin Drug Metab Toxicol. 2018 Feb; 14(2): 219-27.
  42. Hayden F.G., de Jong M.D. Emerging influenza antiviral resistance threats. J Infect Dis. 2011 Jan 1; 203(1): 6-10.
  43. Betakova T., Kostrabova A., Lachova V., Turianova L. Cytokines Induced During Influenza Virus Infection. Curr Pharm Des. 2017; 23(18): 2616-22.
  44. Lee S., Hirohama M., Noguchi M. et al. Influenza A Virus Infection Triggers Pyroptosis and Apoptosis of Respiratory Epithelial Cells through the Type I Interferon Signaling Pathway in a Mutually Exclusive Manner. J Virol. 2018 Jun 29; 92(14). pii: e00396-18.
  45. Shepardson K.M., Larson K., Morton R.V. et al. Differential Type I Interferon Signaling Is a Master Regulator of Susceptibility to Postinfluenza Bacterial Superinfection. MBio. 2016 May 3; 7(3). pii: e00506-16.
  46. Rynda-Apple A., Robinson K.M., Alcorn J.F. Influenza and Bacterial Superinfection: Illuminating the Immunologic Mechanisms of Disease. Infect Immun. 2015 Oct; 83(10): 3764-70.
  47. Robinson K.M., Kolls J.K., Alcorn J.F. The immunology of influenza virus-associated bacterial pneumonia. Curr Opin Immunol. 2015 Jun; 34: 59-67.
  48. Rynda-Apple A., Harmsen A., Erickson A.S. et al. Regulation of IFN-y by IL-13 dictates susceptibility to secondary postinfluenza MRSA pneumonia. Eur J Immunol. 2014 Nov; 44(11): 3263-72.
  49. Carolan L.A., Rockman S., Borg K. et al. Characterization of the Localized Immune Response in the Respiratory Tract of Ferrets following Infection with Influenza A and B Viruses. J Virol. 2015 Dec 30; 90(6): 2838-48.
  50. Sobrevilla-Navarro A.A., Sandoval-Rodriguez A., Garcia-Banuelos J.J. et al. Interferon-a Silencing by Small Interference RNA Increases Adenovirus Transduction and Transgene Expression in Huh7 Cells. Mol Biotechnol. 2018 Apr; 60(4): 251-58.
  51. Xia C., Wolf J.J., Vijayan M. et al. Casein Kinase 1a Mediates the Degradation of Receptors for Type I and Type II Interferons Caused by Hemagglutinin of Influenza A Virus. J Virol. 2018 Mar 14; 92(7). pii: e00006-18.
  52. Jiang H., Shen S.M., Yin J. et al. Influenza virus non-structural protein 1 inhibits the production of interferon β of alveolar epithelial cells upon the infection of influenza A H1N1. Mol Med Rep. 2017 Oct; 16(4): 4553-60.
  53. Song J., Hu Y., Li J. et al. Suppression of the toll-like receptor 7-dependent type I interferon production pathway by autophagy resulting from enterovirus 71 and coxsackievirus A16 infections facilitates their replication. Arch Virol. 2018 Jan; 163(1): 135-44.
  54. Akiyama H., Ramirez N.P., Gibson G. et al. Interferon-Inducible CD169/Siglec1 Attenuates Anti-HIV-1 Effects of Alpha Interferon. Gummuluru S4.J Virol. 2017 Oct 13; 91(21). pii: e00972-17.
  55. Narulla M.S., Alasiri A., Charmier L. et al. Positive and Negative Regulation of Type I Interferons by the Human T Cell Leukemia Virus Antisense Protein HBZ. J Virol. 2017 Sep 27; 91(20). pii: e00853-17.
  56. Canepa C., Imperiale J.C., Berini C.A. et al. Development of a Drug Delivery System Based on Chitosan Nanoparticles for Oral Administration of Interferon-a. Biomacromolecules. 2017 Oct 9; 18(10): 3302-09.
  57. Elbaz T., Elserafy M., Elakel W. et al. Serious Adverse Events with Sofosbuvir Combined with Interferon and Ribavirin: Real-Life Egyptian Experience. J Interferon Cytokine Res. 2017 Aug; 37(8): 348-53.
  58. Weber E., Reynaud Q., Fort R. et al. Immunomodulatory treatments for persistent and chronic immune thrombocytopenic purpura: A PRISMA-compliant systematic review and meta-analysis of 28 studies. Medicine (Baltimore). 2017 Sep; 96(37): e7534.
  59. Ragusa R., Bertino G., Bruno A. et al. Evaluation of health status in patients with hepatitis c treated with and without interferon. Health Qual Life Outcomes. 2018 Jan 17; 16(1):17.
  60. Botonczyk Ł., Siekierska-Hellmann M., Wisniewski P. et al. Epidemiology, risk factors and prognosis of Interferon alpha induced thyroid disorders. A Prospective Clinical Study. Postepy Hig Med Dosw (Online). 2017 Sep 25; 71(0): 842-49.
  61. Sayiner Z.A., Eraydin A., Metin T., Özkaya M. Interferon alpha-induced non-immune thyrotoxicosis treated by plasmapheresis./ BMJ Case Rep. 2017 Sep 25; 2017. pii: bcr-2017-221228.
  62. Jain V., Patel R.K., Kapadia Z. et al. Drugs and hyperglycemia: A practical guide. Maturitas. 2017 Oct; 104: 80-3.
  63. Silva J.L., Faria D.S., Teixeira F., Afonso M.C., Peixoto D. Systemic sclerosis induced by interferon-alfa treatment of melanoma. Acta Reumatol Port. 2017 Jul-Sep; 42(3): 263-64.
  64. Mendieta K.L., Irfan M., Fernandez Faith E. Interferon-alpha induced psoriasis in a teenager. Pediatr Dermatol. 2018 Mar; 35(2): e136-e137.
  65. Fortuna G., Aria M., Schiavo J.H. Drug-induced oral lichenoid reactions: a real clinical entity? A systematic review. Eur J Clin Pharmacol. 2017 Dec; 73(12): 1523-37. doi: 10.1007/s00228-017-2325-0.
  66. Lee G.A., Hess L., Glasson W.J., Whitehead K. Topical Interferon Alpha-2b Induced Reactive Lymphoid Hyperplasia Masquerading as Orbital Extension of Ocular Surface Squamous Neoplasia. Cornea. 2018 Jun; 37(6): 796-98.
  67. Khan Faisal A.W., Nisar S., Ali S.A., Ahmad F. Effects Of Interferon Therapy On Heart. J Ayub Med Coll Abbottabad. 2016 Apr-Jun; 28(2): 276-80.
  68. Cubas-Gaona L.L., Diaz-Beneitez E., Ciscar M. et al. Exacerbated Apoptosis of Cells Infected with Infectious Bursal Disease Virus upon Exposure to Interferon Alpha. J Virol. 2018 May 14; 92(11). pii: e00364-18.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies